Aug. 19, 2021

Does Aduhelm mark the return of science-based medicine?

"While we still lack a complete cause and effect model of Alzheimer’s disease, there is no doubt that the etiology is multifaceted and nonlinear. This accounts for the fact that it takes an incredibly long time for Alzheimer’s disease to develop....

Apple Podcasts podcast player badge
Spotify podcast player badge
YouTube podcast player badge
Amazon Music podcast player badge
Audible podcast player badge
PlayerFM podcast player badge
PocketCasts podcast player badge
Overcast podcast player badge
Castro podcast player badge
RSS Feed podcast player badge
Podchaser podcast player badge
Podcast Addict podcast player badge
Apple Podcasts podcast player iconSpotify podcast player iconYouTube podcast player iconAmazon Music podcast player iconAudible podcast player iconPlayerFM podcast player iconPocketCasts podcast player iconOvercast podcast player iconCastro podcast player iconRSS Feed podcast player iconPodchaser podcast player iconPodcast Addict podcast player icon

"While we still lack a complete cause and effect model of Alzheimer’s disease, there is no doubt that the etiology is multifaceted and nonlinear. This accounts for the fact that it takes an incredibly long time for Alzheimer’s disease to develop. I mention this because one of the major problems with FDA approval has always been that it insists on utilizing the same framework and methodology of approving drugs designed to treat long-term diseases as it would with short-term diseases."

Robert Trent is a graduate student who blogs at Medaphysics.

He shares his story and discusses his KevinMD article, "Does the FDA approval of aducanumab mark the return of science-based medicine?" (https://www.kevinmd.com/blog/2021/07/does-the-fda-approval-of-aducanumab-mark-the-return-of-science-based-medicine.html)